A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis
Status:
Completed
Trial end date:
2019-12-26
Target enrollment:
Participant gender:
Summary
This is an open-label maximum use trial to evaluate ruxolitinib safety and blood levels after
its topical application twice daily to affected areas (≥ 25% BSA) in adolescent and adult
participants with atopic dermatitis (AD) and to determine if its systemic bioavailability
results in any adverse events.